Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 10, 2026

Cisco Redefines Security for the Agentic Era with AI Defense Expansion and AI-Aware SASE

View original at finance.yahoo.com
Cisco Redefines Security for the Agentic Era with AI Defense Expansion and AI-Aware SASE News Summary:Cisco logo (PRNewsfoto/Cisco Systems, Inc.) Cisco is announcing a suite of capabilities to help enterprises securely adopt AI technology while maintaining agent integrity and control of agentic interactions…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AI security teams are now being asked three questions at once: what AI assets do we have, where did they come from, and how will they behave in production as agents interact with tools and third-party services

    80% confidence

  • In the age of AI, safety and security are pre-requisites for adoption, and AI agents bring a whole new set of challenges

    80% confidence

  • With AI BOM and MCP governance plus multi-turn red teaming and real-time guardrails, Cisco AI Defense is targeting the full risk path from the AI supply chain to agentic runtime

    80% confidence

  • Cisco's SASE market share has increased roughly 20% since 2023

    80% confidence

  • Vendors that align networking, security, and policy enforcement are increasingly well-positioned as SASE deployments scale

    80% confidence

  • As agents take on critical enterprise roles, Cisco is developing protections that work both ways: preventing agents from being compromised and controlling what they can access and do on our behalf

    80% confidence

  • For today's CIOs and CISOs, the explosive growth of AI-driven workloads creates both opportunity and risk

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com